Recommended

Novo Nordisk bids $6.5bn for Metsera Therapeutics
MHRA to streamline UK rare disease drug regulatory pathway
Lilly invests €2.6bn in Netherlands manufacturing facility
MHRA recruits first Chief Medical and Scientific Officer
Galapagos to exit cell therapy business
Chiesi expands French metered dose inhaler facility
CPHI Milan to add AI zone for 2026
Hovione invests $100m in US spray drying manufacturing
news

MeiraGTx sells XLRP gene therapy to Janssen

3
SHARES

Janssen will pay up to $415 million for MeiraGTx’s botaretigene sparoparvovec, a gene therapy for treatment of X-linked retinitis pigmentosa (XLRP).

MeiraGTx sells to XLRP gene therapy to Janssen

MeiraGTx has entered into an asset purchase agreement with Janssen Pharmaceuticals for the remaining interests in botaretigene sparoparvovec (bota-vec) a gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP).

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Under the agreement, MeiraGTx is to receive $130 million in upfront and near-term milestone payments.

The company will receive up to an additional $285 million in cash payments upon first commercial sales of bota-vec in the US and EU, as well as for manufacturing technology transfer.

Additionally, J&J will be responsible for any royalty or milestone amounts that become payable on bota-vec to University College London.

Alexandria Forbes, PhD, president and chief executive officer of MeiraGTx said the deal puts the company in a strong financial position and allows it to increase focus on two late-stage clinical programmes in Xerostomia and Parkinson’s disease and on its manufacturing capabilities.

“In addition, we continue to expedite the development of our Riboswitch gene regulation platform prioritising targets in metabolic disease, immunology and oncology, which we believe have the potential to significantly alter outcomes in these broad disease areas,” Dr Forbes added.

Earlier this year Sanofi invested $30 million in MeiraGTx. In return it will receive a right of first negotiation for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology and Inflammation and CNS targets, as well as for GLP-1 and other gut peptides for metabolic disease, and for MeiraGTx’s Phase II Xerostomia programme.

About XLRP

X-linked retinitis pigmentosa is a rare genetic disease, affecting men. It manifests as impaired night vision and peripheral vision loss and can eventually lead to blindness. There are currently no effective treatments for the rare disease.

In January 2019, Janssen entered into a worldwide collaboration and licence agreement with MeiraGTx, to develop, manufacture and commercialise its inherited retinal disease portfolio, including the XLRP gene therapy.

Share via
Share via